LAVA Therapeutics NV

LAVA Therapeutics NV — Investor Presentation (October 2021)

41 slides from LAVA Therapeutics NV's investor presentation, Oct 13, 2021

  1. Slide 1: Fighting Cancer with Precision Gammabody Platform

    1 Fighting Cancer with Precision Gammabody™ Platform Corporate Presentation October 2021 Exhibit 99.1

  2. Slide 2: Legal Disclosure: Forward-looking Statements

    2 Legal Disclosure: Forward-looking Statements @lava therapeutics 2021 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anticipate,” “

  3. Slide 3: Investment Highlights: Gammabody Platform Bispecific Gamma Delta T Cell Engagers

    3 Well-Funded; Experienced Leadership Lead Assets With Multiple Catalysts POC & Broad Applicability Differentiated Approach Proprietary Platform – Gammabody™ Investment Highlights: Gammabody™ Platform Bispecific Gamma Delta T Cell Engagers • Leaders in therapeutic bispecific antibody approaches leve

  4. Slide 4: Established Leadership with Proven Experience in Drug Discovery & Development

    4 EstablishedLeadershipwithProvenExperienceinDrugDiscovery&Development Ton Adang, PhD CDO Paul Parren, PhD EVP, Head of R&D Hansvander Vliet,MD,PhD CSO Steve Hurly, MSc, MBA President & CEO • 25+ years leadership experience in life sciences industry • Former President & CEO, Sesen Bio, a NASDAQ-list

  5. Slide 5: Differentiated Gammabody Pipeline in Hematologic & Solid Tumor Indications

    5 Differentiated Gammabody™ Pipeline in Hematologic & Solid Tumor Indications MM: multiple myeloma CLL: chronic lymphocytic leukemia AML: acute myeloid leukemia PSMA: prostate-specific membrane antigen EGFR: epidermal growth factor receptor mCRPC: metastatic castration-resistant prostate cancer @lav

  6. Slide 6: Gamma Delta T Cells

    6 Gamma Delta T Cells Uniquely suited for an anti-cancer T cell engager approach V9V2 T Cells

  7. Slide 7: T Cells are Uniquely Positioned to Leverage Innate & Adaptive Immunity

    7  T Cells are Uniquely Positioned to Leverage Innate & Adaptive Immunity Adapted from Dranoff G, Nature Rev Cancer 2004; 4: 11-22 Kabelitz D et al., Cell Mol Immunol 2020; 17: 925-939 @lava therapeutics 2021 V9V2 T cells are a natural first line of defense against cancer, with potential to elic

  8. Slide 8: T Cells Present in Many Cancers & Correlate With Favorable Prognosis

    8  T Cells Present in Many Cancers & Correlate With Favorable Prognosis Adapted from Tosolini M et al. Oncoimmunology 2017; 6, e1284723  T cells indicate highest correlation with favorable outcome among all leukocyte subsets analyzed V9V2 T cells are present across a wide array of hematologica

  9. Slide 9: Systemic Activation of V9V2 T Cells Showed Promise

    9 Systemic Activation of V9V2 T Cells Showed Promise Kobayashi H et al., Cancer Immunol Immunother 2011; 60: 1075-1084 Wilhelm M et al., Blood 2003; 102: 200-206 @lava therapeutics 2021 • Systemic activation and proliferation via treatment with V9V2 T cell-based therapy (synthetic phosphoantigen

  10. Slide 10: LAVA's Proprietary Gammabody Platform

    10 LAVA’s Proprietary Gammabody™ Platform Bispecific Gamma Delta T Cell Engagers

  11. Slide 11: Off-the-Shelf Gammabody Platform: Enhances Innate Tumor Recognition

    11 Off-the-Shelf Gammabody™ Platform: Enhances Innate Tumor Recognition by Directing V9V2 T Cells to the Cancer Cells V9V2 T cells recognize stress signals – TCR interacts with pAg-butyrophilin complex Conditionally activate V9V2 T cells upon crosslinking with tumor associated antigen (TAA) Ga

  12. Slide 12: Cascade Response – Potential Translation to Clinical Efficacy Benefit

    12 Cascade Response – Potential Translation to Clinical Efficacy Benefit Efficacy: Safety: In addition to direct tumor cell killing, V9V2 T cells have the potential to orchestrate an immunological cascade response that includes activation of innate and adaptive immune cells in the tumor microenvir

  13. Slide 13: Potent Killing of Cancer Cells in Preclinical Models

    13 Potent Killing of Cancer Cells in Preclinical Models Highly Potent Durable Dose Dependent and Serial Killing Conditional Activation EGFR Gammabody™- Induced Cytotoxicity CD1d Gammabody™ Triggers Lysis of CCRF-CEM Tumor Cells Killing of Primary Colorectal Cancer Cells by EGFR GammabodyTM EGFR Gamm

  14. Slide 14: Expansion & Cascade Response Without Treg Activation in Preclinical Models

    14 Expansion & Cascade Response Without Treg Activation in Preclinical Models Gammabody™ can induce robust gamma delta T cell expansion and can amplify the anti-tumor immune response via downstream activation of other immune cells while avoiding co-activation of immunosuppressive T cells such as Tre

  15. Slide 15: Potent Antitumor Effect Against Patient-Derived Tumor Tissue

    15 0 20 40 60 ✱ Potent Antitumor Effect Against Patient-Derived Tumor Tissue Using Both Autologous PBMC and Tumor-Infiltrating Lymphocytes EGFR Gammabody™ induces potent killing of autologous cancer cells using patient derived V9V2 T cells Tumor-Infiltrating T cells Autologous PBMC Primary CRC CRC

  16. Slide 16: Gammabody Can Selectively Kill Cancer Cells While Sparing Healthy Cells

    16 GammabodyTM Can Selectively Kill Cancer Cells While Sparing Healthy Cells in Hematologic Malignancy and Solid Tumor models Data on file: LAVA Therapeutics N.V. • 2:1 ratio (γδ T cells : Target cells) • Similar CD20 expression levels on C1R neo and B-cells CD20 GammabodyTM Mediated Killing PSMA Ga

  17. Slide 17: Fully Cross-Reactive bsTCEs are Well-Tolerated in Non-Human Primates

    17 Fully Cross-Reactive  bsTCEs are Well-Tolerated in Non-Human Primates • Mild to no clinical signs of toxicity • Low cytokine spike, which did not result in CRS • No clinical chemistry abnormalities • No histopathological abnormalities • Gammabody™ detectable on peripheral blood and lymph node g

  18. Slide 18: CD123 T Cell Engager Vs. a CD123 (CD3-Based) Pan T Cell Engager

    18 CD123  T Cell Engager Vs. a CD123 (CD3-Based) Pan T Cell Engager Adapted from Ganesan et al., Leukemia 2021; 35: 2274-2284 @lava therapeutics 2021 Recent third-party publication compared a CD123  T cell engager to a CD123 (CD3-based) pan T cell engager and showed similar tumor lysis capabilit

  19. Slide 19: Gammabody Platform: Potent, Specific & Well-Tolerated

    19 GammabodyTM Platform: Potent, Specific & Well-Tolerated High Tumor Killing Potency Tumor Specificity Conditional Activation  T cells Regulatory T Cell Activation CRS Potential Low Medium @lava therapeutics 2021

  20. Slide 20: LAVA-051 Activates T Cells and iNK T Cells by Targeting CD1d

    20 LAVA-051 Activates  T Cells and iNK T Cells by Targeting CD1d for the Treatment of CLL, MM & AML

  21. Slide 21: LAVA-051: First-in-Class Gammabody Targeting CD1d

    21 LAVA-051: First-in-Class Gammabody™ Targeting CD1d • Principal Mechanism of Action (MoA): Targets and activates V9V2 T cells in the presence of CD1d-expressing tumor cells • Secondary MoA: Activates iNKT cells against CD1d-expressing tumor cells ‒ Direct cytotoxicity against CD1d-positive tumor

  22. Slide 22: LAVA-051: Targeting CD1d for Hematological Cancers

    22 LAVA-051: Targeting CD1d for Hematological Cancers CD1d is expressed on tumors cells in a high proportion of patients with CLL, MM & AML Data on file: LAVA Therapeutics N.V. @lava therapeutics 2021 CD1d expression (MF index) Isotype Isotype Isotype 0.5 1 2 4 8 16 32 64 128 N=39 N=51 N=85 AML MM C

  23. Slide 23: CD1d Gammabody induced anti-tumor activity of iNKT and V9V2 T cells

    23 CD1d Gammabody™ induced anti-tumor activity of iNKT and V9V2 T cells Gammabody™ triggered V9V2 and iNK T cell activity to control CD1d+ MM tumor cell growth, resulting in substantial improvement of survival CD1d Gammabody™ Extends Survival In Multiple Myeloma Mouse Model PBS PBS + CD1d Gammab

  24. Slide 24: Selectively Kills Cancer Cells & Spares Healthy Cells

    24 Selectively Kills Cancer Cells & Spares Healthy Cells 2h pretreatment 50mM ABP 30’ incubation 10pM or 1nM CD1d GammabodyTM 6h co-culture 1:1:1 ratio CLL CD1d Gammabody™ potently killed CLL patient cells and spared healthy volunteer B cells ex vivo Healthy B Cells Primary CLL De Weerdt I et al., C

  25. Slide 25: LAVA-051 Phase 1/2a Initiated in Hematological Malignancies

    25 CLL AND MM AML (highest dose levels only) Optional adjustments: • Dosing frequency • Dose level •# cohorts CLL (n=20) MM (n=20) Twice-weekly dosing AML (n=20) LAVA-051 Phase 1/2a Initiated in Hematological Malignancies Data from Phase 1 expected in 1H 2022; Phase 2a dose expansion expected in 2H

  26. Slide 26: LAVA-051 Phase 1/2a: Extensive Biomarker Analysis

    26 Biomarker analysis to validate whether LAVA’s Gammabody™ platform performs in humans as predicted based on preclinical data LAVA-051 Phase 1/2a: Extensive Biomarker Analysis Pharmacodynamics Cytokines (IL-1β, IL-2, IL-6, IL-8, TNF-α, IFN-γ, GM-CSF) a. Binding of LAVA-051: V9V2-T cells | CD1d po

  27. Slide 27: Patient Population & US Market Size in Relapsed / Refractory MM, CLL & AML

    27 • PFS = 3-4 mos • ORR = 30-50% • CR = 10-20% • PFS = 6-12 mos • PFS = 4 mos 1 Decision Resources Group; Datamonitor Healthcare; Roche Investor Presentation, 2019 2 Decision Resources Group @lava therapeutics 2021 Multiple Myeloma1 4L Efficacy, Current Standard of Care3,4,5 * = transplant-eligible

  28. Slide 28: Feasible Threshold for Accelerated Approval Pathway in RRMM

    28 Feasible Threshold for Accelerated Approval Pathway in RRMM Pivotal Studies Efficacy N ORR mDOR 97 24% 4.2 mos 97 31% 11 mos 83 21% 3.8 mos @lava therapeutics 2021 PEPAXTO (Oncopeptides) – Feb 2021 Indication: failed ≥4 lines of therapy, triple-class refractory disease BLENREP (GSK) – May 2020 In

  29. Slide 29: LAVA-1207 Activates T Cells by Targeting PSMA for mCRPC

    29 LAVA-1207 Activates  T Cells by Targeting PSMA for the Treatment of mCRPC

  30. Slide 30: LAVA-1207: Targeting PSMA for Prostate Cancer

    30 LAVA-1207: Targeting PSMA for Prostate Cancer • Specifically targets and activates V9V2 T cells against PSMA-expressing tumor cells • PSMA is a well-validated tumor target ‒ Mediates PSMA-dependent activation of V9V2 T cells resulting in potent killing of PSMA-positive tumor cells • Fc added

  31. Slide 31: LAVA-1207: Targeting PSMA for Prostate Cancer

    31 LAVA-1207: Targeting PSMA for Prostate Cancer Butyrophilin (BTN3A) & PSMA are elevated on tumor cells in samples of prostate cancer patients PSMA is a validated target. LAVA-1207, a PSMA Gammabody™, demonstrated potent, dose dependent cytotoxicity and is a potential first-in-class therapeutic for

  32. Slide 32: PSMA Gammabody demonstrates preferential killing of tumor cells

    32 PSMA GammabodyTM demonstrates preferential killing of tumor cells while sparing healthy cells ex vivo PSMA Gammabody™ Selectivity in Preclinical Models PSMA-Mediated Killing PSMA Gammabody™ **** p<0.001 Data on file: LAVA Therapeutics N.V. @lava therapeutics 2021 Medium + PSMA Gammabody™ + V9V2

  33. Slide 33: Unmet Need Remains In mCRPC: Initial Opportunity in 3rd Line

    33 30 20 10 0 5 10 15 20 25 30 35 1L 2L 3L 2020 Treated Patients (‘000) US Treated Population 3 LAVA HCP Market Research 4 Product PIs Unmet Need Remains In mCRPC: Initial Opportunity in 3rd Line 1 Decision Resources Group; Datamonitor Healthcare; AstraZeneca, Feb. 14, 2020; SVBLeerink, April 22, 20

  34. Slide 34: LAVA-1207 Phase 1/2a in Metastatic Castration-Resistant Prostate Cancer

    34 Therapy Refractory mCRPC Optional Adjustments: • Dosing frequency • Dose level •# cohorts Therapy Refractory mCRPC (n=30) Dosing: Every 2 Weeks LAVA-1207 Phase 1/2a in Metastatic Castration-Resistant Prostate Cancer (mCRPC) LAVA-1207 Phase 1/2a Expected to Begin in Q421 Dose Escalation Dose Expan

  35. Slide 35: Key Preclinical Programs

    35 Key Preclinical Programs 35

  36. Slide 36: Potential for LAVA-1223 Across EGFR-Expressing Solid Tumors

    36 Potential for LAVA-1223 Across a Number of EGFR-Expressing Solid Tumors Data on file: LAVA Therapeutics N.V. and Janssen Biotech Inc. @lava therapeutics 2021 0 20 40 60 80 100 Bladder Breast Colon Glioma Head & Neck NSCLC Ovarian Pancreatic RCC Percentage overexpression range EGFR Expression by T

  37. Slide 37: CD40 Gammabody for Multiple Solid Tumors & Hematologic Malignancies

    37 CD40Gammabody™ forMultipleSolidTumors & Hematologic Malignancies De Weerdt I et al., Cancer Immunol Res 2021; 9: 50-61 @lava therapeutics 2021 • CLL • DLBCL • MM Hematologic Malignancies Solid Tumors • Bladder • Colon • Esophageal • Lung • Ovarian • Melanoma • Renal • Pancreatic • Prostate • Thym

  38. Slide 38: Milestones

    38 Milestones 38

  39. Slide 39: LAVA Now Clinical Stage - Two Lead Programs Expected in Clinic in 2021

    39 P1: Dose Escalation • 3L+ mCRPC pts • Adoptive FIH study design, dose escalation • Key data: Safety, initial anti-tumor activity, estimation of therapeutic window • Initial study in relapsed/refractory MM, CLL; relapsed/refractory AML added at biological relevant dose(s) • Adoptive FIH study desi

  40. Slide 40: Investment Highlights: Gammabody Platform Bispecific Gamma Delta T Cell Engagers

    40 Well-Funded; Experienced Leadership Lead Assets With Multiple Catalysts POC & Broad Applicability Differentiated Approach Proprietary Platform – Gammabody™ Investment Highlights: Gammabody™ Platform Bispecific Gamma Delta T Cell Engagers • Leaders in therapeutic bispecific antibody approaches lev

  41. Slide 41: Fighting Cancer with Precision Gammabody Platform

    41 Fighting Cancer with Precision Gammabody™ Platform Corporate Presentation October 2021

LAVA Therapeutics — Investor Presentation (October 2021) on 6ix